SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 8/22/2017 2:19:21 PM - Followers: 718 - Board type: Free - Posts Today: 59

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Initial Statement of Beneficial Ownership (3) 08/08/2017 04:18:08 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:17:33 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:17:00 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:16:36 PM
IPIX News: Current Report Filing (8-k) 07/13/2017 04:04:10 PM
PostSubject
#193431  Sticky Note Leo has done an outstanding job managing available biodoc 08/13/17 03:48:53 PM
#192669  Sticky Note TODAY 8-7-17 ---> Press Release: Innovation Pharmaceuticals Completes TheHound 08/07/17 08:24:08 AM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#190524  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets, Blogs sox040713 07/16/17 03:13:55 PM
#187089  Sticky Note Prurisol's Importance: data We are nearing the very DaubersUP 06/23/17 04:59:13 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#194273   Ive been trying to buy all day at DaubersUP 08/22/17 02:21:50 PM
#194272   If the SP is increased by 10x to sox040713 08/22/17 02:19:21 PM
#194271   Doc, you've made some excellent posts today. I sox040713 08/22/17 02:11:50 PM
#194270   I don't know. There are several possible TheMonolith 08/22/17 02:07:08 PM
#194269   Hi Sox, Probably because it would be a TheBunny 08/22/17 02:04:50 PM
#194267   I was talking about the market cap if sox040713 08/22/17 01:46:23 PM
#194266   Good point! Management has taken huge risks in mdphd2008 08/22/17 01:40:47 PM
#194265   Management can't buy with all the clinical data sox040713 08/22/17 01:38:02 PM
#194264   Monolith, why did Leo and Dr. Menon defer sox040713 08/22/17 01:29:14 PM
#194262   Bunny, why did Leo and Dr. Menon defer sox040713 08/22/17 01:28:08 PM
#194260   Thanks for the info. Isn't 2 major pieces mdphd2008 08/22/17 12:49:05 PM
#194259   Force officers to buy shares? Who does TheMonolith 08/22/17 12:41:37 PM
#194258   Not short at all. Way too long. MXAMDUD 08/22/17 12:40:10 PM
#194257   I would recapitalize the company. Do a MXAMDUD 08/22/17 12:38:31 PM
#194256   Better ask the guys in sales. dooshbag 08/22/17 12:36:52 PM
#194255   Please give us your detailed business plan as 1oldprof 08/22/17 12:31:54 PM
#194253   Although you make some valid points, and in mdphd2008 08/22/17 12:24:03 PM
#194252   love to sell - have way too many MXAMDUD 08/22/17 12:20:04 PM
#194250   tell that to all the PHD's on this MXAMDUD 08/22/17 12:04:44 PM
#194249   Thats all great. You sound accomplished and intelligent. MXAMDUD 08/22/17 12:03:02 PM
#194248   And some hope that management would pay retail TheBunny 08/22/17 11:56:23 AM
#194247   I don't agree with your point. Can you please mdphd2008 08/22/17 11:54:02 AM
#194246   none of this matters. its all noise unless MXAMDUD 08/22/17 11:42:21 AM
#194245   Yes!! It is an excellent institution with a mdphd2008 08/22/17 11:16:22 AM
#194244   Dartmouth is an ivy league school. Very good reputation. Jhawker 08/22/17 11:15:08 AM
#194243   Is that an institution with a good reputation,..? cabel 08/22/17 11:11:22 AM
#194242   Here is new site for K-OC - http://cancer.dartmouth.edu/patients/clinical_trial/ DaubersUP 08/22/17 10:58:37 AM
#194241   Seems like the new location is probably: Dartmouth-Hitchcock Jhawker 08/22/17 10:57:09 AM
#194240   info on 9/8 conference ----> TheHound 08/22/17 10:15:10 AM
#194239   After today only 11 more trading days till BooDog 08/22/17 10:06:57 AM
#194237   the market has decided untohim 08/22/17 10:04:58 AM
#194236   He probably will not have results before September 8 groton68 08/22/17 10:02:59 AM
#194235   That is very encouraging news, shows they have mdphd2008 08/22/17 10:01:34 AM
#194234   its simply amazing to me how mgmt has MXAMDUD 08/22/17 09:53:32 AM
#194233   no concern for shareholders @IPIX Giovanni 08/22/17 09:44:24 AM
#194232   stock getting pounded yet again. this is MXAMDUD 08/22/17 09:36:22 AM
#194230   the market has decided Giovanni 08/22/17 09:32:48 AM
#194228   its going to be yet another red day MXAMDUD 08/22/17 09:30:27 AM
#194227  Restored The SP is the true condition of the company. Giovanni 08/22/17 09:28:38 AM
#194226   Another site now recruiting for Kevetrin OC. runninggirl2016 08/22/17 09:28:25 AM
#194225   The September conference can't possibly be "a great scottsmith 08/22/17 09:27:31 AM
#194224   When JnJ and K were discussed in last Amatuer17 08/22/17 09:22:26 AM
#194223   I will be glad when it is over untohim 08/22/17 09:20:23 AM
#194222   It's likely that Leo didn't mention interim results LilBigKahuna 08/22/17 09:16:23 AM
#194221   IPIX's short interest is negligible. TheHound 08/22/17 09:11:14 AM
#194220   another weak day on tap. This is MXAMDUD 08/22/17 09:11:14 AM
#194219   I am assuming we will get the Interim cabel 08/22/17 09:10:23 AM
#194218   "We will also highlight the major events upcoming scottsmith 08/22/17 08:59:47 AM
#194217   After today only 11 more trading days till cabel 08/22/17 08:36:32 AM
#194215   IPIX Johnson and Johnson could be knocking on the Echo20 08/22/17 07:35:39 AM
PostSubject